CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review
Por:
Hernani R, Sancho A, Amat P, Hernández-Boluda JC, Pérez A, Piñana JL, Carretero C, Goterris R, Gómez M, Saus A, Ferrer B, Teruel AI, Terol MJ and Solano C
Publicada:
1 oct 2021
Ahead of Print:
1 jul 2021
Resumen:
Patients with postransplant lymphoproliferative disease (PTLD) who are refractory to rituximab-based regi-mens have extremely poor prognosis. Data is lacking in the setting of solid organ transplantation (SOT)-related PTLD treated with chimeric antigen receptor T-cell (CAR-T) therapy. Moreover, limited information is available on the influence of concomitant immunosuppressive drugs on CAR-T function. Here, we describe the clinical outcome in one PTLD patient and propose a strategy for tailoring immunosuppressive treatment and organ monitoring in patients with kidney allografts after CAR-T infusion. This report also reviews the limited published data in the setting of SOT-related PTLD treated with CAR-T, which appears to be a feasible treatment in this clinical scenario, without severe toxicity and capable of inducing sustained responses. A noteworthy finding is that in most reported cases patients underwent complete or partial discontinuation of immunosuppressive drugs, with only one documented case of allograft rejection. (c) 2021 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Filiaciones:
Hernani R:
Haematology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, 17 Blasco Ibáñez Avenue, 46010 Valencia, Spain
:
Nephrology Department, Hospital Universitario Dr. Peset, Valencia, Spain
Amat P:
Haematology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, 17 Blasco Ibáñez Avenue, 46010 Valencia, Spain
Department of Medicine, University of Valencia, Valencia, Spain
Hernández-Boluda JC:
Haematology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, 17 Blasco Ibáñez Avenue, 46010 Valencia, Spain
Department of Medicine, University of Valencia, Valencia, Spain
Pérez A:
Haematology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, 17 Blasco Ibáñez Avenue, 46010 Valencia, Spain
Piñana JL:
Haematology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, 17 Blasco Ibáñez Avenue, 46010 Valencia, Spain
CIBERONC, Instituto Carlos III, Madrid, Spain
Carretero C:
Haematology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, 17 Blasco Ibáñez Avenue, 46010 Valencia, Spain
Goterris R:
Haematology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, 17 Blasco Ibáñez Avenue, 46010 Valencia, Spain
Gómez M:
Haematology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, 17 Blasco Ibáñez Avenue, 46010 Valencia, Spain
Saus A:
Haematology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, 17 Blasco Ibáñez Avenue, 46010 Valencia, Spain
Ferrer B:
Haematology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, 17 Blasco Ibáñez Avenue, 46010 Valencia, Spain
Teruel AI:
Haematology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, 17 Blasco Ibáñez Avenue, 46010 Valencia, Spain
Department of Medicine, University of Valencia, Valencia, Spain
Terol MJ:
Haematology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, 17 Blasco Ibáñez Avenue, 46010 Valencia, Spain
Department of Medicine, University of Valencia, Valencia, Spain
Solano C:
Haematology Department, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, 17 Blasco Ibáñez Avenue, 46010 Valencia, Spain
Department of Medicine, University of Valencia, Valencia, Spain
hybrid
FULL TEXT
 |
Published Version |
|
| No Accesible |
|